EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1

Akeem Sanni iD, Mona Goli, Jingfu Zhao, Junyao Wang iD, Chloe Barsa, Samer El Hayek iD, Farid Talih, Bartolo Lanuzza, Firas Kobeissy iD, Giuseppe Plazzi, Monica Moresco, Stefania Mondello iD und 2 weitere

Biomolecules · 2023

DOI: 10.3390/biom13030420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Akeem Sanni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry and Biochemistry Department, Texas Tech University, Lubbock, TX 79409, USA. Hauptthemen laut MEDLINE: Proteomics, Narcolepsy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narcolepsy type 1 (NT1) is the most common type of narcolepsy known to be caused by the loss of specific neurons responsible for producing peptide neurotransmitters (orexins/hypocretins), resulting in a sleep-wake cycle disorder. It is characterized by its association with cataplexy and abnormalities in rapid eye movement. To date, no cure has been established for this life-threatening condition. Misdiagnosis of NT1 is also quite common, although it is not exceedingly rare. Therefore, successfully identifying candidate serum biomarkers for NT1 would be a head start for accurate diagnosis and development of therapeutics for this disorder. This study aims to identify such potential serum biomarkers. A depletion protocol was employed for 27 human serum samples (16 NT1 and 11 healthy controls), followed by applying LC-MS/MS bottom-up proteomics analysis, then LC-PRM-MS for validation. The comparison of the proteome profiles of the low-abundant proteins in the samples was then investigated based on age, sex, sample groups, and the presence of the Human Leukocyte Antigen (HLA) DQB1*0602 allele. The results were tracked to gene expression studies as well as system biology to identify key proteins and understand their relationship in the pathogenesis of NT1. Our results revealed 36 proteins significantly and differentially expressed. Among the impaired pathways and bioprocesses, the complement activation pathway is impaired by six of the differentially expressed proteins (DEPs). They are coded by the genes C2, CFB, C5, C1R, C1S, and MASP1, while 11 DEPs are involved in Acute Phase Response Signaling (APRS), which are coded by the genes FN1, AMBP, APOH, CFB, CP, ITIH2, C5, C2, F2, C1, and ITIH4. The combined AUCs of the downregulated and upregulated DEPs are 0.95 and 0.76, respectively. Overall, this study reveals potential serum-protein biomarkers of NT1 and explains the possible correlation between the biomarkers and pathophysiological effects, as well as important biochemical pathways involved in NT1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsNarcolepsyHumansChromatography, LiquidTandem Mass SpectrometryBiomarkersOrexins

Stichwörter der Autor:innen

NT1autoimmunityorexin/hypocretinpathophysiologyserum-protein biomarkers

Substanzen

BiomarkersOrexins

Autor:innen und Institutionen

  • Chemistry and Biochemistry Department, Texas Tech University, Lubbock, TX 79409, USA.
  • Faculty of Biochemistry and Molecular Genetics, American University of Beirut, Beirut 1107 2020, Lebanon.
  • Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33124, USA.
  • Department of Psychiatry, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
  • Sleep Research Centre, Department of Neurology IC, Oasi Research Institute-IRCCS, 94018 Troina, Italy.
  • Multiomics & Biomarkers, Department of Neurobiology, Center for Neurotrauma, Morehouse School of Medicine (MSM), Atlanta, GA 30310, USA.

ORCID-Profile: Akeem Sanni, Junyao Wang, Samer El Hayek, Firas Kobeissy, Stefania Mondello, Raffaele Ferri, Yehia Mechref

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Italian Ministry of Health Ricerca Corrente (RC)
  • Robert A. Welch Foundation
  • CH Foundation

Zitieren

APA

Sanni, A., Goli, M., Zhao, J., Wang, J., Barsa, C., El Hayek, S., Talih, F., Lanuzza, B., Kobeissy, F., Plazzi, G., Moresco, M., Mondello, S., Ferri, R., & Mechref, Y. (2023). LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1. Biomolecules. https://doi.org/10.3390/biom13030420

Vancouver

Sanni A, Goli M, Zhao J, Wang J, Barsa C, El Hayek S, et al. LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1. Biomolecules. 2023. doi:10.3390/biom13030420

BibTeX
@article{Sanni2023,
  author = {Sanni, Akeem and Goli, Mona and Zhao, Jingfu and Wang, Junyao and Barsa, Chloe and El Hayek, Samer and Talih, Farid and Lanuzza, Bartolo and Kobeissy, Firas and Plazzi, Giuseppe and Moresco, Monica and Mondello, Stefania and Ferri, Raffaele and Mechref, Yehia},
  title = {LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13030420}
}
Kostenlos starten →